title: Molecular simulations of drug-receptor complexes in anticancer research.
abstract: Molecular modeling and computer simulation techniques have matured significantly in recent years and proved their value in the study of drug-DNA, drug-DNA-protein, drug-protein and protein-protein interactions. Evolution in this area has gone hand-in-hand with an increased availability of structural data on biological macromolecules, major advances in molecular mechanics force fields and considerable improvements in computer technologies, most significantly processing speeds, multiprocessor programming and data-storage capacity. The information derived from molecular simulations of drug-receptor complexes can be used to extract structural and energetic information that is usually beyond current experimental possibilities, provide independent accounts of experimentally observed behavior, help in the interpretation of biochemical or pharmacological results, and open new avenues for research by posing novel relevant questions that can guide the design of new experiments. As drug-screening tools, ligand- and fragment-docking platforms stand out as powerful techniques that can provide candidate molecules for hit and lead development. This review provides an overall perspective of the main methods and focuses on some selected applications to both classical and novel anticancer targets.
authors.affiliation: Department of Pharmacology, University of Alcalá, lcalá de Henares, Madrid, Spain. federico.gago@uah.es
authors.forename: Federico
authors.initials: F
authors.lastname: Gago
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008870:Microtubules / Q000737:chemistry / Q000378:metabolism; D056004:Molecular Dynamics Simulation; D009369:Neoplasms / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011506:Proteins / Q000737:chemistry / Q000378:metabolism; D050257:Tubulin Modulators / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations; D047428:Protein Kinase Inhibitors; D011506:Proteins; D050257:Tubulin Modulators; D004247:DNA; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl